PROCEPT BioRobotics Corporation PRCT
22.37 USD +1.75 (+8.49%)
At closeNov 10, 2026, 7:25 AM EST
22.36 -0.01 -0.04%
Pre-market · Nov 10, 7:25 AM ET
20.67 Day range 22.62
16.67 52-week range 38.11
- YTD
- -28.89%
- 1 year
- -27.70%
News
benzinga.com Truist Securities Maintains Hold on PROCEPT BioRobotics, Raises Price Target to $24 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Hold and raises the price target from $21 to $24.
benzinga.com UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21 UBS analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral and raises the price target from $20 to $21.
benzinga.com Leerink Partners Maintains Market Perform on PROCEPT BioRobotics, Raises Price Target to $22 Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Market Perform and raises the price target from $20 to $22.
marketbeat.com PROCEPT BioRobotics Q3 Earnings Call Highlights PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements…
seekingalpha.com PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
zacks.com PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.38 per share a year ago.
benzinga.com PROCEPT BioRobotics Q3 2026 Earnings Call Transcript PROCEPT BioRobotics (NASDAQ:PRCT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $395.409M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $395.409 million estimate.
globenewswire.com PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing…- benzinga.com Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30 Barclays analyst Christopher Pasquale initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight rating and announces Price Target of $30.
benzinga.com TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $28 TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $34 to $28.
benzinga.com Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25 Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.
benzinga.com Evercore ISI Group Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $23 Evercore ISI Group analyst Vijay Kumar maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $30 to $23.- benzinga.com William Blair Downgrades PROCEPT BioRobotics to Market Perform William Blair analyst Brandon Vazquez downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform.
- benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $397.424M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $397.424 million estimate.
- benzinga.com PROCEPT BioRobotics Q2 EPS $(0.47) Misses $(0.46) Estimate, Sales $94.498M Beat $92.893M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent. This is a 34.29 percent decrease over losses…
benzinga.com Truist Securities Downgrades PROCEPT BioRobotics to Hold, Lowers Price Target to $25 Truist Securities analyst Richard Newitter downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Buy to Hold and lowers the price target from $30 to $25.
benzinga.com This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Wall Street analysts upgraded various top stocks, including Nucor, Varonis, Invitation Homes, and Macerich. See what experts say about NUE.
benzinga.com This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts changed outlook on top names, see all changes on Benzinga's analyst ratings page. Check out views on BB, SLGL, PRCT, OGE, TTWO.- benzinga.com Evercore ISI Group Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $30 Evercore ISI Group analyst Vijay Kumar initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform rating and announces Price Target of $30.
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q2 Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold, according to Benzinga Pro. iRhythm, Procept Biorobotics, Anbio Biotechnology among lowest RSI values.
benzinga.com This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page and analysts' views before buying MKTX stock.- benzinga.com Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform, Lowers Price Target to $29 Leerink Partners analyst Mike Kratky downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform and lowers the price target from $31 to $29.
benzinga.com PROCEPT BioRobotics Announces Two Milestones In Its WATER IV Prostate Cancer Clinical Program PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation®…- benzinga.com Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Raises Price Target to $35 Piper Sandler analyst Matt O'Brien reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $28 to $35.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $396.674M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $396.674 million estimate.
- benzinga.com PROCEPT BioRobotics Q1 EPS $(0.56), Inline, Sales $83.132M Beat $80.506M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.56) per share which met the analyst consensus estimate. This is a 24.44 percent decrease over losses of $(0.45) per share from the…
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com Baird Initiates Coverage On PROCEPT BioRobotics with Neutral Rating, Announces Price Target of $30 Baird analyst David Rescott initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral rating and announces Price Target of $30.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $30 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $47 to $30.
benzinga.com Leerink Partners Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $30 Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $55 to $30.- benzinga.com TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $34 TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $50 to $34.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $28 Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $50 to $28.
- benzinga.com Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $34 Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $51 to $34.
benzinga.com C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com PROCEPT BioRobotics Stock Hits 52-Week Low - Here's Why PROCEPT BioRobotics (NASDAQ: PRCT) shares down on Q4 2025 results and updated revenue guidance. Q1 sales expected at $79-82 million.
benzinga.com Forecasting The Future: 5 Analyst Projections For PROCEPT BioRobotics 
benzinga.com Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com PROCEPT BioRobotics Sees Q1 Sales $79.000M-$82.000M vs $92.646M Est PROCEPT BioRobotics (NASDAQ:PRCT) sees Q1 sales of $79.000 million-$82.000 million vs $92.646 million analyst estimate.
- benzinga.com PROCEPT BioRobotics Q4 EPS $(0.53) Misses $(0.32) Estimate, Sales $76.383M Miss $94.137M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.32) by 67.19 percent. This is a 51.43 percent decrease over losses…
- benzinga.com PROCEPT BioRobotics Lowers FY2026 Sales Guidance from $410.000M-$430.000M to $390.000M-$410.000M PROCEPT BioRobotics (NASDAQ:PRCT) lowers FY2026 sales outlook from $410.000 million-$430.000 million to $390.000 million-$410.000 million.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com What's Next: PROCEPT BioRobotics's Earnings Preview 
benzinga.com A Peek at PROCEPT BioRobotics's Future Earnings